N
NextCure D
D
NXTC
0.45550
USD
-0.05
(-9.80%)
مغلق
حجم التداول
0
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
12,776,862
الأخبار المقالات
العنوان: NextCure
القطاع: Healthcare
الصناعة: Biotechnology
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.